Payment overview · 2025
General Payments
$1,056.10
55 reported records · 15 companies
Healthcare provider profile · identity verified
Gregory Benjamin Floyd, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CARROLLTON, GA · NPI 1326066895
Verified facts
What the public records show
CMS Open Payments records show Gregory Benjamin Floyd, M.D. received $1,056.10 in general payments during 2025 across 55 reported records.
Novo Nordisk Inc accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nexletol, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $209.71 | 19.9% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $152.01 | 14.4% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.21 | 14.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $127.92 | 12.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.41 | 9.1% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.26 | 5.6% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $58.81 | 5.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.33 | 3.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.48 | 3.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.29 | 2.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.35 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.06 | 1.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.13 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.20 | 1.5% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $13.93 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,042.17 | 54 |
| Entertainment | $13.93 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $133.00 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $104.42 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $86.65 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $86.45 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $80.96 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $65.56 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $65.56 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $63.85 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $59.26 | 3 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $58.81 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.89 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.33 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.47 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.77 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
95 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 561 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 556 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 471 | 138 |
| Gabapentin | Gabapentin | 368 | 93 |
| Alprazolam | Alprazolam | 306 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 277 | 77 |
| Omeprazole | Omeprazole | 265 | 69 |
| Losartan Potassium | Losartan Potassium | 259 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 255 | 71 |
| Metformin Hcl | Metformin Hcl | 235 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 230 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 68 |
| Lisinopril | Lisinopril | 215 | 60 |
| Clonazepam | Clonazepam | 213 | 38 |
| Meloxicam | Meloxicam | 194 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 193 | 59 |
| Famotidine | Famotidine | 186 | 60 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 176 | 33 |
| Pregabalin | Pregabalin | 167 | 46 |
| Furosemide | Furosemide | 156 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 44 |
| Tramadol Hcl | Tramadol Hcl | 145 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 32 |
| Carvedilol | Carvedilol | 131 | 42 |
| Temazepam | Temazepam | 125 | 26 |
| Potassium Chloride | Potassium Chloride | 121 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 31 |
| Trazodone Hcl | Trazodone Hcl | 108 | 27 |
| Meclizine Hcl | Meclizine Hcl | 104 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 19 |
| Allopurinol | Allopurinol | 103 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 30 |
| Montelukast Sodium | Montelukast Sodium | 100 | 26 |
| Rybelsus | Semaglutide | 95 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 27 |
| Eliquis | Apixaban | 92 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 24 |
| Chlorthalidone | Chlorthalidone | 85 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 24 |
| Ozempic | Semaglutide | 78 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 15 |
| Metformin Hcl Er | Metformin Hcl | 76 | 22 |
| Buspirone Hcl | Buspirone Hcl | 69 | 14 |
| Linzess | Linaclotide | 68 | 19 |
| Trulicity | Dulaglutide | 67 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 17 |
| Simvastatin | Simvastatin | 62 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 17 |
| Carisoprodol | Carisoprodol | 57 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 11 |
| Sertraline Hcl | Sertraline Hcl | 55 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 22 |
| Azithromycin | Azithromycin | 53 | 45 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 12 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Glipizide Er | Glipizide | 47 | 14 |
| Mirtazapine | Mirtazapine | 47 | 13 |
| Myrbetriq | Mirabegron | 47 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Jardiance | Empagliflozin | 46 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 37 |
| Baclofen | Baclofen | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 42 | 23 |
| Celecoxib | Celecoxib | 41 | 12 |
| Finasteride | Finasteride | 41 | 13 |
| Donepezil Hcl | Donepezil Hcl | 40 | 14 |
| Sulindac | Sulindac | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 11 |
| Prednisone | Prednisone | 34 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 13 |
| Sucralfate | Sucralfate | 34 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Scopolamine | Scopolamine | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Nystatin | Nystatin | 27 | 17 |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Topiramate | Topiramate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 11 |
| Belsomra | Suvorexant | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nexletol | Bempedoic Acid | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Methscopolamine Bromide | Methscopolamine Bromide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,056.10 · 55 records | Novo Nordisk Inc | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, Cologuard Collection Kit, DAYBUE, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NFC-700, NURTEC ODT, OCT OPHTHALMOSCOPE, OTEZLA, PANORAMIC OPHTHALMOSCOPE, PREVNAR 20, REPATHA, SHINGRIX, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error